Macupatide (LY3532226) is a Lilly investigational compound named in several registered studies alongside eloralintide. Those studies are still running, and none has posted results. This page lists what the registry says about them and nothing more.
We do not describe macupatide’s mechanism here, because we have not confirmed it from a primary source. Eloralintide is an investigational amylin receptor agonist; its mechanism is covered on our mechanism pages.
The registered studies
| Study | Population | Design and size | Status (checked 2026-10-01) | Main question |
|---|---|---|---|---|
| NCT07215559 | Adults with obesity or overweight and type 2 diabetes | Phase 2, double-blind, placebo-controlled. Macupatide and eloralintide alone or together. 200 planned. | Recruiting. Started 2025-10-16. Primary completion 2027-03. | Percent change in body weight at week 32. |
| NCT07589608 | Adults with obesity or overweight, without type 2 diabetes | Phase 2b, double-blind, placebo-controlled. 400 planned. Runs under the master protocol below. | Recruiting. Started 2026-05-15. Primary completion 2027-09. | Percent change in body weight at week 36. |
| NCT07765511 | Japanese adults with obesity or overweight, without type 2 diabetes | Multiple-dose study of macupatide alone and with eloralintide. 60 planned. | Not yet recruiting. Registered start 2026-10. | Treatment-related serious adverse events at week 25. |
| NCT06143956 | Master protocol for chronic weight management | An umbrella protocol, not a single trial with one result. 1,481 planned. | Recruiting. Primary completion 2027-09. | Sets entry rules for separate intervention-specific studies. |
Source: ClinicalTrials.gov registry records, read on 2026-10-01. Registry status changes, so check each record for the current state.
What this does and does not show
A registry record shows that a study exists and how it is designed. It does not show that the combination works, that it is safe, or that it will be approved. No efficacy or safety results have been posted for these studies, so any figure you see attributed to a macupatide and eloralintide combination should be traced to a primary source before you rely on it.
Not the same as EloraTZP
EloraTZP is eloralintide combined with tirzepatide, not with macupatide. Lilly announced topline Phase 2 results for that combination on 2026-09-30 (study NCT06603571). Those figures are sponsor-reported, were not peer reviewed at the time, and come from a type 2 diabetes population. See our eloralintide and tirzepatide comparison and the reported side effects page.
Related
Phase 2 results · ENLIGHTEN Phase 3 program · Eloralintide CAS number and identifiers
This page is informational. Eloralintide and macupatide are investigational and not approved. Nothing here is medical advice or a recommendation for human use.
Related reading: every registered eloralintide clinical trial, with current status.